Because Good Medicine Deserves Better Explanations
Cholesterol-lowering medications are being prescribed to almost 30% of US adults aged 40 and over, most of these are statins drugs (1). The number increases with age, and approximately 48% of adults older than 75 are receiving such treatment. It has been suggested that treating more older individuals with statins may prevent a substantial number of cardiovascular events, and that, … Read more
The results from the recent GLAGOV trial suggest that aggressive lowering of LDL-cholesterol with a PCSK9-inhibitor on top of statin therapy in patients with coronary artery disease may reduce atherosclerotic plaque burden. Although these results provide support for the lipid hypothesis and may have significant implications for the future of cardiovascular medicine, our eyes are still on safety and … Read more
In the midst of the obesity epidemic, one of our most important concerns is the association between body mass index (BMI) and the risk of cardiovascular disease (CVD). However, body weight itself may not be what matters most. Evidence suggests that obesity measures such as BMI, waist circumference, or waist-to-hip ratio, assessed singly or in combination, … Read more
Apolipoprotein E (ApoE) is one of the proteins the body uses to transport fats (lipids) in the bloodstream from one tissue or cell type to another. It is essential for healthy metabolism of cholesterol and triglycerides, two important types of fats the body has to deal with regularly. The relationship between ApoE and heart disease has been studied quite intensively in recent … Read more
Data presented at the World Heart Federation’s World Congress of Cardiology & Cardiovascular Health 2016 (WCC 2016) in Mexico City may radically change our perspective on how carbohydrates and different types of fats affect blood cholesterol and other lipid biomarkers. The presentation was based on data from the Prospective Urban Rural Epidemiological (PURE) study. The data have not been … Read more